SCHEMBL4348609

SCHEMBL4348609

O=C(Nc1ccc(OC(F)(F)F)cc1)Nc1cc(Cl)ccc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.64
NTRK1 P04629 1/20 0.59
CDK19 Q9BWU1 1/20 0.59
IGF1R P08069 2/20 0.56
CHRNA7 P36544 1/20 0.55
IDH1 O75874 1/20 0.54
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA9 Q16790 1/20 0.53
FAAH O00519 1/20 0.52
P2RX1 P51575 1/20 0.52
GRIK1 P39086 3/20 0.51
STING1 Q86WV6 1/20 0.51
P2RY1 P47900 3/20 0.50
TDP1 Q9NUW8 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
MEN1 O00255 1/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1462221 0.86 P2RX1 (0.71) EPHX2NTRK1CDK19CHRNA7CA12
SCHEMBL4923807 0.85 EPHX2 (0.83) EPHX2IGF1RIDH1CA12CA1
SCHEMBL4354666 0.84 EPHX2 (0.62) EPHX2IGF1RIDH1FAAHSTING1
SCHEMBL1883373 0.83 CA12 (0.71) EPHX2NTRK1CDK19CHRNA7CA12
SCHEMBL4346945 0.83 NTRK1 (0.74) EPHX2NTRK1CDK19CHRNA7CA12
SCHEMBL4343951 0.83 EPHX2 (0.69) EPHX2IGF1RIDH1CA12CA1
SCHEMBL24824526 0.82 P2RX1 (0.75) P2RX1MEN1KMT2A
SCHEMBL4358450 0.81 CA12 (0.68) NTRK1CDK19CA12CA1CA2
SCHEMBL11555827 0.80 EPHX2 (1.00) EPHX2FAAHSTING1TDP1NPC1
SCHEMBL26697230 0.80 EPHX2 (0.64) EPHX2IGF1RIDH1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1402887-A1 New compounds for the inhibition of undesired cell proliferation and use thereof Jerini AG (DE) 2004-03-31 EP claimed
EP-1402888-A1 The use of substituted carbocyclic compounds as rotamases inhibitors Jerini AG (DE) 2004-03-31 EP claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 EPHX2 769/4885NTRK1 2802/4885CDK19 1461/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 EPHX2 627/4885NTRK1 3171/4885CDK19 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.